In This Article:
SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of tumors. The application has been accepted by the Center for Drug Evaluation of National Medical Products Administration of China (Application Number: CXHL2401105, CXHL2401107, CXHL2401108).
Malignant tumors are one of the main causes leading to human death. Although clinical treatments have been significantly improved, most tumors are still incurable. The drug resistance, tumor recurrence and metastasis still are the biggest threat to long-term survival of patients. Particularly, Malignant brain tumors and brain metastasis not only brings direct life hazards but also has a natural barrier for drug efficacy due to the blood-brain barrier. Therefore, developing new anti-tumor drugs with good brain permeability has become a hot and difficult topic in improving the current tumor therapy.
CS231295 is a novel brain-penetrating small-molecule, multi-target protein kinase inhibitor independently developed by Chipscreen Biosciences, with proprietary intellectual property rights. This drug candidate exhibits significant synthetic lethal effects on tumors carrying particular genetic defects, providing a new treatment option for patients with such tumors. Additionally, it demonstrates potent anti-tumor angiogenesis activity, resulting in broad-spectrum anti-tumor efficacy. In the future, CS231295, either as a monotherapy or in combination with other anti-tumor drugs, is expected to offer differentiated and innovative treatment options for various types of cancer. Due to its excellent blood-brain barrier permeability, CS231295 possesses significant therapeutic advantages for Malignant brain tumors and metastatic brain tumors, with particularly strong potential for treating primary and metastatic brain tumors. In preclinical studies, CS231295 has shown significant pharmacodynamic activity, favorable pharmacokinetic properties, and a good safety profile.
About Chipscreen:
Chipscreen Biosciences is an innovative drug company driven by core technologies with globally competitive pipelines. As a pioneer in drug innovation & development in China, adhering to the concept of "Constant Innovation for Life", we focus on developing revolutionary innovative drugs with new mechanisms of action, to address patients' pressing clinical needs. Our complete industry chain that covers early exploratory discovery through commercialization allows us to provide innovative Chinese drugs for patients worldwide.